Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics (NASDAQ: HOTH) announced its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The company cites Bitcoin's growing investor acceptance, recent ETF approvals, and increased institutional investor activity as key factors in this decision. CEO Robb Knie emphasized Bitcoin's potential as an inflation-resistant store of value and its emergence as a major asset class.
Hoth Therapeutics (NASDAQ: HOTH) has reported promising early data from a preclinical study of its cancer treatment HT-KIT, conducted at NC State University. The preliminary results show that the treatment effectively stabilized tumor growth with remarkable consistency across subjects. Key findings include stabilized tumor volumes in treated subjects, high consistency across treated animals with minimal error bars, and notable differences compared to untreated controls which showed greater variability and increased tumor volume.
Hoth Therapeutics (NASDAQ: HOTH) has been granted a U.S. patent for its innovative Alzheimer's treatment, HT-ALZ. This breakthrough therapy targets the Substance P/Neurokinin-1 Receptor pathway, which is important in neuroinflammation, a key factor in Alzheimer's progression. Preclinical studies have shown promising results, including reduced neuroinflammation and improved cognitive functions.
The company is now preparing for human clinical trials, with formulation of HT-ALZ currently underway. The upcoming trials will focus on demonstrating the drug's safety, tolerability, and effectiveness in addressing cognitive decline associated with Alzheimer's disease. This patent secures Hoth's intellectual property rights and strengthens its position in Alzheimer's therapy development.
Hoth Therapeutics (NASDAQ: HOTH) has announced promising preclinical results for its Alzheimer's drug candidate, HT-ALZ. The study, conducted on Alzheimer's model mice, showed significant reductions in astrocyte activity in key brain areas after treatment with HT-ALZ. Notably, the hippocampus showed decreased astrocyte coverage at both 20 mg and 40 mg dose levels compared to the control group, with similar trends observed in the cortex.
These reductions in reactive astrocytes corresponded with improved cognitive performance, suggesting a potential link between HT-ALZ's effect on astrocytic activity and therapeutic benefits. The company is conducting further analysis to determine if the treatment is affecting the size or total number of astrocytes. CEO Robb Knie expressed confidence in these results as Hoth Therapeutics advances HT-ALZ through further studies and clinical trials.
Hoth Therapeutics (NASDAQ: HOTH) has expanded its clinical sites for the HT-001 Phase 2a trial, adding Dana-Farber Cancer Institute in Boston and Montefiore Medical Center in New York. The trial, approved by Institutional Review Boards, aims to evaluate HT-001 for treating skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This First-in-Human study will assess the efficacy, safety, and tolerability of topical HT-001. CEO Robb Knie expressed optimism about the trial's potential to help cancer patients suffering from EGFRi-related skin toxicities. Notably, Hoth ended the previous quarter with over $9 million in cash and has no plans for further capital raising in 2024.
Hoth Therapeutics (NASDAQ: HOTH) has announced positive data from a first-of-its-kind human patient treatment using HT-001 for epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs). The patient, a 59-year-old female with metastatic breast cancer, experienced significant symptom improvement after just one week of treatment, allowing her to discontinue HT-001 after only seven days. This rapid success highlights HT-001's potential as an effective therapy for EGFRI-associated skin toxicities, which affect up to 90% of cancer patients undergoing EGFRI therapy. A Phase 2a clinical trial is currently underway to further evaluate HT-001's efficacy and safety, with multiple prestigious cancer centers participating in the study.
Hoth Therapeutics (NASDAQ: HOTH) has entered a Master Services Agreement with Aronnax Inc. for its HT-KIT cancer therapeutic. Aronnax will oversee ITR Laboratories in conducting intravenous injection studies to determine the Maximum-Tolerated Dose (MTD) and perform a Dose Range-Finding Phase for HT-KIT.
HT-KIT, an antisense oligonucleotide targeting the proto-oncogene cKIT, has shown promising results in killing human mast cells and reducing KIT expression in GIST and AML cells. It has received Orphan Drug Designation from the FDA for treating mast cell-derived cancers and anaphylaxis.
This study aims to provide Hoth with key metrics for formulating its proposed clinical trial, advancing HT-KIT towards an IND-enabling study.
Hoth Therapeutics (NASDAQ: HOTH) has partnered with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer's disease treatment. This collaboration follows promising pre-clinical results that demonstrated HT-ALZ's ability to improve cognitive functions and quality of life in subjects with Alzheimer's.
The treatment showed potential to reduce brain inflammation, leading to improved cognitive outcomes. Pre-clinical research indicated HT-ALZ's capacity to enhance memory tasks related to the hippocampus and sensorimotor gating. The prototype development will support a future Investigational New Drug (IND) Application to initiate clinical trials, marking a significant step in Hoth's innovative approach to Alzheimer's treatment.
Hoth Therapeutics (NASDAQ: HOTH) has expanded its First-in-Human Phase 2a clinical trial for HT-001, a treatment for skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. The company received approval from three prestigious medical centers: GW University Hospital, UC Irvine, and Northwell Health.
The trial aims to investigate the efficacy, safety, and tolerability of topical HT-001. CEO Robb Knie expressed optimism that the trial will demonstrate successful delivery of their lead therapeutic candidate and provide hope for cancer patients suffering from EGFRi-related skin toxicities. More information about this dose-ranging study is available on clinicaltrials.gov.
Hoth Therapeutics (NASDAQ: HOTH) has entered a joint development agreement with Wise Systems International SRL, using Nvidia's BioNeMo generative AI platform. This collaboration aims to accelerate the drug discovery process by utilizing AI for target identification and lead optimization. The partnership is expected to enhance Hoth's therapeutic pipeline and increase the value of its assets. Key executives from both companies expressed optimism about leveraging AI to bring innovative treatments to patients.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
